PHILADELPHIA, Penn. (January 26, 2009)-Thermo Fisher Scientific Inc., the world leader in serving science, today introduced significant functionality enhancements to Darwin LIMS, its purpose-built Laboratory Information Management System (LIMS) designed specifically for pharmaceutical manufacturing R&D and QA/QC. Already offering dissolution, stability management, product and batch management, environmental monitoring and system interfacing, Thermo Scientific Darwin 3.0 brings new capabilities to pharmaceutical labs.
Darwin 3.0's new fully validated web interface allows for more efficient reporting and sharing of test data across the lab. Built on the Microsoft .NET framework, Darwin can easily be extended to include dashboard-ready tools for multi-user and multi-site environments where the interface gives immediate information on resource and instrument utilization so laboratory managers can maximize productivity by optimizing resources.
Darwin 3.0 also features solution and reagent inventory management and built-in instrument calibration and maintenance, allowing continuous operations and increased efficiencies. Reagent lots and amounts are logged and tracked over time, ensuring that a test is never stopped due to lack of reagent availability or a bad/expired lot. Likewise, instrument calibration and maintenance tracking prevents a user from running a test on an uncalibrated or out of compliance instrument. "Building this functionality into the core Darwin product provides organizations with the assurance that they are fully compliant and meeting regulatory requirements at all times," said Gary Walz, Darwin Product Manager, Thermo Fisher Scientific.
Pharmaceutical labs will realize a lower total cost of ownership due to Darwin's user-friendly and intuitive interface, as well as the
industry-specific functionality that is built into the product, reducing the need for costly customization to standardize processes. The product was designed and optimized to operate on the Oracle 10g platform, with extensive interfacing capabilities to provide tight integration with SAP for rapid batch disposition and release and streamlined workflow, plus new historical data trending and charting functionality. The embedded charting and trending for product stability testing allows for real-time data review and rapid reporting. By incorporating SAP and additional systems interfacing capabilities, as well as batch and product management capabilities, customers are better prepared to integrate Darwin into their global enterprise landscape.
"Our goal with Darwin has been to deliver as much domain-specific, out-of-the-box functionality to our customers as possible. Version 3.0 addresses not only the critical needs of the pharmaceutical laboratory, but also brings with it the increased functionality multi-site/multi-user labs are looking for. These new features clearly position Darwin as the definitive solution for the pharmaceutical industry. Darwin lowers the cost, risk and time associated with implementation, training, validation, maintenance and upgrades compared to generic LIMS that require costly customizations," says Dave Champagne, vice president and general manager for Informatics, Thermo Fisher Scientific.
The newest features built into the latest release of Darwin have been designed to meet FDA regulations, and brings pharmaceutical labs time savings in validation efforts, and cost savings in personnel and production time. Darwin 3.0, with its built-in dashboard ready functionality, will allow pharmaceutical lab managers to make faster decisions and, with reduced validation time, bring their drugs to market sooner.
For more information about Thermo Scientific informatics solutions, please call + 1 866 463 6522, e-mail marketing.informatics@thermofisher.com or visit www.thermo.com/informatics.
Thermo Scientific is part of Thermo Fisher Scientific, the world leader in serving science.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, we have more than 30,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier
brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.